(0.13%) 5 106.40 points
(0.13%) 38 288 points
(0.10%) 15 943 points
(-1.24%) $82.81
(4.94%) $2.02
(0.08%) $2 349.10
(0.01%) $27.54
(3.89%) $958.00
(-0.17%) $0.933
(-0.23%) $11.00
(-0.44%) $0.797
(1.74%) $93.47
@ $0.771
发出时间: 15 Feb 2024 @ 02:55
回报率: -8.64%
上一信号: Feb 14 - 04:34
上一信号:
回报率: -0.05 %
Live Chart Being Loaded With Signals
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States...
Stats | |
---|---|
今日成交量 | 484 560 |
平均成交量 | 2.69M |
市值 | 84.09M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $-0.370 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.270 |
ATR14 | $0.00300 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Fust Matthew K | Buy | 150 000 | Common Stock |
2024-03-31 | Heiden William K | Buy | 150 000 | Common Stock |
2024-03-31 | Roncarolo Maria Grazia | Buy | 150 000 | Common Stock |
2024-03-31 | Gallagher Carol Giltner | Buy | 150 000 | Common Stock |
2024-03-31 | Mallik Ameet | Buy | 150 000 | Common Stock |
INSIDER POWER |
---|
70.32 |
Last 100 transactions |
Buy: 8 350 944 | Sell: 2 074 393 |
音量 相关性
Atara Biotherapeutics Inc 相关性 - 货币/商品
Atara Biotherapeutics Inc 财务报表
Annual | 2023 |
营收: | $8.57M |
毛利润: | $-313 000 (-3.65 %) |
EPS: | $-2.61 |
FY | 2023 |
营收: | $8.57M |
毛利润: | $-313 000 (-3.65 %) |
EPS: | $-2.61 |
FY | 2022 |
营收: | $63.57M |
毛利润: | $49.01M (77.08 %) |
EPS: | $-2.24 |
FY | 2021 |
营收: | $20.34M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.63 |
Financial Reports:
No articles found.
Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。